araag2/HINT huggingface dataset:
Clinical trial NCT03531905 (phase 2, status: completed)
Conditions: diabetes, diabetes mellitus, type 2, cholesterolemia
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bempedoic acid + ezetimibe fdc oral tablet, ezetimibe 10 mg oral tablet, placebo oral tablet, placebo oral capsule
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes for 6 months or greater

          -  Currently taking stable diabetes medication for 3 months or greater

          -  HbA1c between 7-10%

          -  LDL-cholesterol greater than 70 mg/dL

          -  Women must not be pregnant, lactating, or planning to become pregnant within 30 days
             after last dose of study medication; and must be postmenopausal, surgically sterile,
             or willing to use 1 acceptable form of birth control during the study through 30 days
             after the last dose of study medication

        Exclusion Criteria:

          -  Body mass index > 40 kg/m2

          -  History of documented clinically significant cardiovascular disease

          -  Fasting triglycerides > 400 mg/dL

          -  History of Type 1 diabetes

          -  Uncontrolled hypothyroidism, liver dysfunction, renal dysfunction, gastrointestinal
             condition that may affect drug absorption, hematologic or coagulation disorder or
             active malignancy

          -  History of drug or alcohol abuse within 2 years
Clinical trial NCT03546621 (phase 2, status: completed)
Conditions: chronic hepatitis d infection with hepatitis b
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: myrcludex b, myrcludex-b, myrcludex-b, tenofovir
SMILES: C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age from 18 to 65 years inclusively at the time of signing Informed Consent Form.

          2. Positive serum HBsAg for at least 6 months before Screening.

          3. Positive serum anti-HDV antibody for at least 6 months before screening.

          4. Positive PCR results for serum HDV RNA at Screening.

          5. Patients with liver cirrhosis, irrespective of previous interferon treatment .

          6. Patients without liver cirrhosis, who failed prior interferon treatment or for whom,
             in the opinion of the Investigator, such treatment is currently contraindicated
             (including history of interferon intolerance) .

          7. Alanine aminotransferase level >1 x ULN, but less than 10 x ULN.

          8. Previous nucleotide/nucleoside analogue treatment within at least 12 weeks prior to
             the planned start of study treatment or subject's willingness to take tenofovir for at
             least 12 weeks prior to the planned start of study treatment.

          9. Negative urine pregnancy test for females of childbearing potential.

         10. Inclusion criteria for female subjects:

               -  Postmenopausal for at least 2 years, or

               -  Surgically sterile (total hysterectomy or bilateral oophorectomy, bilateral tubal
                  ligation, staples, or another type of sterilization), or

               -  Abstinence from heterosexual intercourse throughout the study, or

               -  Willingness to use highly effective contraception throughout the study and for 3
                  months after the last dose of the study medication.

         11. Male and female subjects must agree to use a highly effective contraception throughout
             the study and for 3 months after the last dose of the study medication.

         12. Male subjects must agree not to donate sperm throughout the study and for 3 months
             after the last dose of the study medication.

        Exclusion Criteria:

          1. Child-Pugh score of B-C or over 6 points.

          2. HCV or HIV coinfection. Subjects with anti-HCV antibodies can be enrolled, if
             screening HCV RNA test is negative.

          3. Creatinine clearance <60 mL/min.

          4. Total bilirubin ≥ 2mg/dL. Patients with higher total bilirubin values may be included
             after the consultation with the Study's Medical Monitor, if such elevation can be
             clearly attributed to Gilbert's syndrome associated with low-grade hyperbilirubinemia.

          5. Any previous or current malignant neoplasms, including hepatic carcinoma.
Clinical trial NCT03569033 (phase 2, status: terminated)
Conditions: acute cough
ICD codes: R05.1
Drugs: gefapixant, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the data did not support study endpoints for acute cough, based on an interim efficacy
    analysis; not due to safety concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          -  In good general health

          -  Susceptible to human rhinovirus type 16 (HRV-16)

          -  Male or non-pregnant and non-breast feeding female

          -  If female of reproductive potential, agrees to use 1 form of acceptable birth control

        Exclusion Criteria:

          -  Donated blood within 56 days or donated plasma within 7 days prior to dosing

          -  History of significant multiple and/or severe allergies

          -  Recent history of respiratory tract infection

          -  History of cancer

          -  Body mass index <18 kg/m^2 or ≥40 kg/m^2

          -  History of major surgery or loss of 1 unit of blood

          -  History of allergic reaction to sulfonamides

          -  Received medications within 14 days prior to randomization

          -  Significantly abnormal laboratory tests at Screening

          -  Current smoker, smoked within 5 years of Screening, or significant past smoking
             history

          -  History of alcohol or drug abuse
Clinical trial NCT03576638 (phase 2, status: unknown status)
Conditions: parkinson disease
ICD codes: G20
Drugs: accordion pill carbidopa/levodopa, sinemet cr 25mg-100mg extended-release tablet
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. diagnosis of PD consistent with UK Brain Bank Criteria

          2. Stable dose of levodopa/carbidopa IR for at least 4 weeks prior to entry; taking at
             least 4 doses of IR levodopa during waking hours, and total daily dose of at least
             400mg prior to initial screening

          3. Stable on all anti-PD medications for 30 days prior to screening. COMT inhibitors are
             held prior to PK studies on day 1 through day 8

        Exclusion Criteria:

          1. Atypical or secondary parkinsonism

          2. clinically significant cardiac, pulmonary, hepatic, or renal disease or other
             condition which contraindicates participation in judgement of investigator

          3. severe dyskinesia as assessed by PI

          4. significant cognitive impairment

          5. Clinically significant psychiatric illness in opinion of PI

          6. history of small bowel or gastric surgery (including PEG-J placement for
             Duopa/Duodopa) or bowel obstruction, diagnosis of small bowel narrowing, diagnosis of
             Crohn's disease, frequent nausea or emesis regardless of etiology, and symptomatic
             gastroparesis.

          7. History of GI pathology of clinical significance as determined by PI

          8. Allergy to study drug or Yellow Dye #5 (tartrazine)

          9. Unable to swallow large pills

         10. Active GERD and regular use of PPIs

         11. Women who are pregnant or nursing or are of childbearing potential who are not willing
             to use a medically acceptable method of contraception
Clinical trial NCT03591458 (phase 2, status: terminated)
Conditions: type1 diabetes mellitus, hypoglycemia unawareness
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: amitriptyline, placebo
SMILES: CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow subject enrollment, unable to complete trial in a timely manner
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with Type 1 Diabetes Mellitus for at least 5 years or more

          -  Age between 21 to 60 years old

          -  HbA1c less or equal to 9% with the latest measurement within the last 3 months

          -  Use of real time Continuous Glucose Monitoring (rtCGM) providing continuous glucose
             data points for at least 3 months, and at least 80% of CGM readings available over the
             last 2-week period

          -  Able to provide informed consent and willing to sign an approved consent form that
             conforms to federal and institutional guidelines

        Exclusion Criteria:

          -  Ongoing or recent history of major depressive disorder, or other ongoing major
             psychiatric disorders

          -  History of anti-depressant use within the last three months

          -  Insulin pump linked to a CGM with programmed automatic insulin adjustment or
             suspension

          -  History of advanced cardiac, liver, kidney or neurological disease

          -  Active malignancy

          -  Uncontrolled Human Immunodeficiency Virus diseases

          -  Advanced diabetic retinopathy, neuropathy, or nephropathy

          -  Frequent acetaminophen use which can disrupt CGM accuracy

          -  Pregnancy or female of child-bearing potential unable to practice effective
             contraception during the study period

          -  Breastfeeding female, or female with prospective plan to initiate breastfeeding

          -  Ongoing history of alcohol abuse

          -  Contraindication to amitriptyline use, including hypersensitivity to amitriptyline or
             any component of the formulation, co-administration with or within 14 days of
             Monoamine Oxidase Inhibitors and co-administration with cisapride

          -  Inability to understand or cooperate with study procedures, including taking study
             drugs and recording hypoglycemic symptoms.

        The participants meeting the above criteria will enter "Run-in Period". At the Visit 2, the
        following additional exclusion criteria will be applied before study drug randomization:

          -  < 80% of CGM readings available over the last 2-week period

          -  Time spent in hypoglycemia (i.e., < 70 mg/dL) for < 5% over a 2-week period on based
             on CGM reading.
Clinical trial NCT03592862 (phase 2, status: withdrawn)
Conditions: dementia with lewy bodies
ICD codes: G31.83
Drugs: htl0018318, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    pending investigation of an unexpected animal toxicology finding.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with probable DLB according to the fourth revision of consensus diagnostic
             criteria for DLB.

          -  Clinical imaging evidence from either SPECT or MIBG cardiac scintigraphy that is
             consistent with a clinical diagnosis of DLB.

          -  Partner or caregiver able to support the patient for the duration of the clinical
             trial.

        Exclusion Criteria:

          -  Patients with a diagnosis of Parkinson disease at least 1 year prior to onset of
             dementia.

          -  Patients with the presence of severe extrapyramidal symptoms

          -  Patients with the presence of an illness/condition apart from DLB that could
             contribute to cognitive dysfunction

          -  Patients with poorly controlled hypertension despite lifestyle modifications and/or
             pharmacotherapy, who are currently on more than 2 different antihypertensive
             treatments

          -  Patients with prominent, recurrent episodes of syncope are related to orthostatic
             hypotension

          -  Patients with pulmonary disease or evidence of clinically significant moderate or
             severe pulmonary symptoms

          -  Patients who are taking a range of prohibited and restricted medication

          -  Patients who have been prescribed individualised cognitive rehabilitation, stimulation
             or training that was performed under medical supervision in the 6 months prior to the
             screening visit

          -  Patients who have any known condition(s) that may be contraindicated or interfere with
             the completion of the nuclear imaging scans.
Clinical trial NCT03595579 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: axs-05, bupropion
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1, CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Currently meets DSM-5 criteria for MDD

          -  Body mass index (BMI) between 18 and 40 kg/m^2, inclusive

          -  Agree to use adequate method of contraception for the duration of the study

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Suicide risk

          -  History of treatment resistance in current depressive episode

          -  History of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic
             stimulation or any experimental central nervous system treatment during the current
             episode or in the past 6 months

          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study

          -  Additional criteria may apply
Clinical trial NCT03595644 (phase 2, status: recruiting)
Conditions: stage iv non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: tki
SMILES: C#CC1=CC=CC(NC2=NC=NC3=CC4=C(OCCOCCOCCO4)C=C23)=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Patients must have biopsy proven metastatic NSCLC (Stage IV).

          2. Patients must have received first line chemotherapy, from 4-6 cycles, and achieved
             stable disease or a partial response.

          3. Patients receiving first-line erlotinib, gefitinib, or icotinib for EGFR
             mutant-positive for 3 months and achieved stable disease, partial response or
             completely response.

          4. Age 18 to 75 years old.

          5. Patients must have measurable disease at baseline.

          6. The amount of metastatic focus <5.

          7. ECOG score 0-2

          8. Adequate normal organ and marrow function for TKI treatment and radiotherapy.

          9. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R)

         10. Patients must provide written informed consent to participate in the study.

        Exclusion Criteria:

          1. Patients who previously received radiotherapy to the primary site.

          2. Patient can't tolerate radiotherapy or targeted therapy;

          3. Pregnant or nursing women
Clinical trial NCT03597139 (phase 2, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: voclosporin ophthalmic solution, restasis®
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. Have a best corrected visual acuity (BCVA) in both eyes of +0.7 logarithm of the
             Minimum Angle of Resolution (logMAR) or better as assessed by Early Treatment of
             Diabetic Retinopathy Study (ETDRS) chart.

          2. Have a documented history of DED in both eyes supported by a previous clinical
             diagnosis.

          3. Have ongoing DED, as defined by at least one eye (if one eye, the same eye) meeting
             all the following criteria:

               -  A symptom severity score of ≥30 for Eye Dryness on a Visual Analog Scale (VAS)
                  (0-100)

               -  An unanesthetized Schirmer Tear Test (STT) score of ≥1 mm and ≤10 mm per 5
                  minutes (Note: STT Score obtained at Visit 1)

               -  Evidence of ocular surface staining (total fluorescein staining score of at least
                  3 [0-15 scale]).

          4. Have normal lid anatomy.

        Exclusion Criteria:

          1. Have any known hypersensitivity or contraindication to study treatments (including
             excipients), topical anesthetics or vital dyes.

          2. Be unable to demonstrate correct instillation of over-the-counter (OTC) ocular
             lubricant.

          3. Report discomfort in both eyes from instillation of OTC ocular lubricant during Visit
             2 (based on score of ≥30 on the Drop Discomfort VAS).

          4. Have used Restasis® (cyclosporine ophthalmic emulsion) within 30 days prior to Visit
             1.

          5. Have used Restasis® for more than 1 month (if prior use is reported).

          6. Have used Xiidra® (lifitegrast ophthalmic solution) within 14 days prior to Visit 1.

          7. Have had corneal graft surgery in either eye within 1 year.

          8. Have recent or current evidence of ocular infection or inflammation in either eye.

          9. Have current evidence of clinically significant blepharitis (defined as requiring lid
             hygiene therapy), conjunctivitis, or a history of herpes simplex or zoster keratitis
             in either eye.
Clinical trial NCT03598777 (phase 2, status: terminated)
Conditions: vulvodynia
ICD codes: N94.818, N94.819
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal

          -  Have vulvodynia for at least 6 months and for no more than 15 years

          -  Have provoked pain at the vestibule on a Q tip test

        Exclusion Criteria:

          -  Deep pain during intercourse

          -  Have genitourinary or gastrointestinal conditions which may interfere with the study

          -  Previous surgery that according to investigator's judgement may impact on study
             outcome (including but not limited to hysterectomy, vestibulectomy, urologic surgery,
             perianal surgery) or genital trauma or mutilation/cutting
Clinical trial NCT03608839 (phase 2, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: intravitreous dexamethasone solution 4mg/ml - vol 0,01 ml, intravitreous dexamethasone solution 4mg/ml - vol 0,03 ml, intravitreous dexamethasone solution 4mg/ml - vol 0,05 ml
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  age > = 18 years;

          -  diagnosis of DM type 2;

          -  pseudophakic patients

          -  presence of clinically significant DME according to ETDRS guidelines;

          -  best correct visual acuity (BCVA) between 20/400 and 20/40;

          -  central macular thickness (CMT) >= 300 µm measured by spectral domain optical
             coherence tomography ( Spectralis® Heidelberg). If both eyes of the patient met the
             elegibility criteria, the eye with worse BCVA at baseline was designated as the study
             eye.

        Exclusion Criteria:

          -  any treatment of DME in the previous 4 months;

          -  pan retinal photocoagulation (PRP) in the previous 4 months or antecipated need of PRP
             for the next 6 months;

          -  any ophthalmologic surgery performed in the previous 4 months;

          -  history of pars plana vitrectomy;

          -  history of open-angle glaucoma or intraocular pressure elevation induced by
             corticosteroids that required anti-glaucomatous treatment or anti- hypertensive ocular
             treatment;

          -  intraocular pressure >= 21 mmHg;

          -  patients with characteristics that meet the inclusion criteria, but refused to sign
             the written general consent.
Clinical trial NCT03614065 (phase 2, status: unknown status)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: endostar, placebos
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  NSCLC Brain metastasis

        Exclusion Criteria:

          -  KPS<60
Clinical trial NCT03633461 (phase 2, status: completed)
Conditions: dry eye disease
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: oc-02, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have used and/or desired to use an artificial tear substitute for dry eye symptoms
             within 60 days prior to Visit 1

        Exclusion Criteria:

          -  Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such
             as blepharoplasty) in either eye within three months or refractive surgery (e.g. laser
             epithelial keratomileusis, laser-assisted in-situ keratomileusis, photorefractive
             keratectomy or corneal implant) within twelve months of Visit 1

          -  Have a history or presence of any ocular disorder or condition in either eye that
             would, in the opinion of the Investigator, likely interfere with the interpretation of
             the study results or participant safety such as significant corneal or conjunctival
             scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis,
             or inflammation not associated with dry eye; anterior (epithelial) basement membrane
             corneal dystrophy or other clinically significant corneal dystrophy or degeneration;
             ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring
             treatment and mild meibomian gland disease that are typically associated with DED are
             allowed.

          -  Have a systemic condition or disease not stabilized or judged by the Investigator to
             be incompatible with participation in the study or with the lengthier assessments
             required by the study (e.g., current systemic infection, uncontrolled autoimmune
             disease, uncontrolled immunodeficiency disease, history of myocardial infarction or
             heart disease, etc.)

          -  Have a known hypersensitivity to any of the procedural agents or study drug components

          -  Have any condition or history that, in the opinion of the investigator, may interfere
             with study compliance, outcome measures, safety parameters, and/or the general medical
             condition of the subject